149 related articles for article (PubMed ID: 33430727)
1. Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
Cao M; Li T; Chen Y; Zhai X
Mini Rev Med Chem; 2021; 21(11):1337-1350. PubMed ID: 33430727
[TBL] [Abstract][Full Text] [Related]
2. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
[TBL] [Abstract][Full Text] [Related]
3. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
4. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
5. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
6. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
7. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
8. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
10. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract][Full Text] [Related]
11. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
14. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
[TBL] [Abstract][Full Text] [Related]
16. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
17. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
[TBL] [Abstract][Full Text] [Related]
19. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
